会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • SUSCEPTIBILITY TO DASATINIB
    • 对DASATINIB的敏感性
    • WO2010020619A2
    • 2010-02-25
    • PCT/EP2009/060641
    • 2009-08-17
    • MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.UNIVERSITÄT ZU KÖLNTHOMAS, RomanSOS, MartinWEISS, JonathanZANDER, ThomasFROMMOLT, Peter
    • THOMAS, RomanSOS, MartinWEISS, JonathanZANDER, ThomasFROMMOLT, Peter
    • C12Q1/68
    • C12Q1/6886C12Q1/6841C12Q2537/157C12Q2600/106C12Q2600/136
    • The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to dasatinib. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with dasatinib is described herein. Furthermore, an in vitro method for the identification of a responder for or a patient sensitive to an dasatinib is disclosed and uses of an oligo- or polynucleotide capable of detecting (an) the amplification status of at least one gene selected from the group consisting of SRC, EPHA3, FRK, EPHA5, EPHA8, YES, ABL2, LCK and BLK gene are provided. The present invention also relates to a method of diagnosing non-small cell lung cancer and a method of monitoring the efficacy of a treatment of said cancer. In addition, a method of predicting the efficacy of a cancer treatment is described, in particular a non-small cell lung cancer. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one amplified marker gene as defined herein for screening and/or validation of a medicament for the treatment of said cancer is described and a kit useful for carrying out the methods described herein is provided.
    • 本发明涉及选择(a)细胞,(a)组织或(a)对达沙替尼具有易感性的细胞培养物的方法。 本文还描述了用于测定哺乳动物肿瘤细胞或癌细胞对达沙替尼治疗的反应性的方法。 此外,公开了鉴定对达沙替尼敏感的应答者或患者的体外方法,以及能够检测(a)选自以下的至少一种基因的扩增状态的寡核苷酸或多核苷酸的用途: 提供SRC,EPHA3,FRK,EPHA5,EPHA8,YES,ABL2,LCK和BLK基因。 本发明还涉及诊断非小细胞肺癌的方法和监测所述癌症治疗功效的方法。 另外,描述了预测癌症治疗功效的方法,特别是非小细胞肺癌。 还描述了用于筛选和/或验证用于治疗所述癌症的药物的(转基因)非人动物或具有至少一种如本文所定义的扩增的标记基因的(转基因)细胞的用途,以及用于 执行本文所述的方法。